



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

5 RCE
1653
PTO/SB/30 (10/2001)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/692,938
Filing Date	October 20, 2000
First Named Inventor	Meyerhoff
Art Unit	1653
Examiner Name	Gupta
Attorney Docket Number	Army 126

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR §1.114

a. Previously submitted

i. Consider the amendment(s)/reply under 37 CFR §1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).

ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
iii. Other _____

b. Enclosed

i. Amendment/Reply iii. Information Disclosure Statement (IDS)
ii. Affidavit(s)/Declaration(s) iv. Other _____

2. Miscellaneous

a. Suspension of action on the above-identified application is requested under 37 CFR §1.103(c) for a period of _____ months (Period of suspension shall not exceed 3 months; Fee under 37 CFR §1.17(i) required)

b. Other _____

3. Fees The RCE fee under 37 CFR §1.17(e) is required by 37 CFR §1.114 when the RCE is filed.

a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 21-0380

i. RCE fee required under 37 CFR §1.17(e) 03/03/2003 AWDHDAF1 00000116 210380 09692938
ii. Extension of time fee (37 CFR §§1.136 and 1.17) 01 FC:1801 750.00 CH
iii. Other _____

b. Check in the amount of \$ _____ enclosed

c. Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print / Type)

Caroline Nash

Registration No. (Attorney / Agent)

~~2029~~ 36,329

Signature

Date

February 21, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark

Name (Print / Type)

Caroline Nash

Signature

Date

February 21, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): Meyerhoff, et al.

Docket No.

Army 126

Serial No.
09/692,938Filing Date
October 20, 2000Examiner
Gupta, AnishGroup Art Unit
1653

Invention: A PHARMACEUTICAL COMPOSITION CONTAINING PGLU-GLU-PRO-NH2 AND METHOD FOR
TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	11 -	20 =	0	x \$18.00	\$0.00
INDEP. CLAIMS	6 -	6 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable)	<input type="checkbox"/>				\$0.00
		TOTAL ADDITIONAL FEE FOR THIS AMENDMENT			\$0.00

No additional fee is required for amendment.

Please charge Deposit Account No. in the amount of
A duplicate copy of this sheet is enclosed.

A check in the amount of to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No.
A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 CFR 1.17.


Signature

Dated: February 21, 2003

Caroline Nash, Reg. No. 36,329

Nash & Titus, LLC

3415 Brookeville Road


Brookeville, MD 20833

(301) 924-9500

for: Elizabeth Arwine, Reg. No. 45,867

Fort Detrick, MD 21702-9223

I certify that this document and fee is being deposited
February 21, 2003 with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231.


Signature of Person Mailing Correspondence

Caroline Nash

Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of
Meyerhoff, et al.

Serial No.: 09/692,938

Filed: October 20, 2000

RECEIVED

MAR 04 2003 Group Art Unit: 1653

TECH CENTER 1600/2900 Examiner: Gupta, Anish

11/8
M9.3
3/12/03

FOR: A PHARMACEUTICAL COMPOSITION CONTAINING PGLU-GLU-PRO-NH₂
AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN,
SPINAL CORD AND RETINA USING SAME

* * * * *

AMENDMENT

Asst. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Responsive to the Office Action dated October 22, 2002, please enter the following amendments and consider the following remarks.

IN THE CLAIMS:

Please cancel claims 9 and 12.

Please amend the claims as follows:

B1
1. (Twice Amended) A pharmaceutical composition comprising a neuroprotective amount of pGLU-GLU-PRO-amide as an active ingredient and a pharmaceutically acceptable carrier, wherein said neuroprotective amount is an amount sufficient to reduce Glu induced neurotoxicity in brain, spinal cord and/or retina.

B2
7. (Twice Amended) A method of reducing Glu induced neurotoxicity in brain, spinal cord and/or retina comprising administering to a patient a composition comprising a